Showing results (361-370 of 722) with videos related to

Sort By:
Pageof 73
The Lancet. Haematology|March 28, 2020
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 studyPaul G Richardson, Sara Bringhen, Peter Voorhees, et al.
The Lancet. Haematology|March 30, 2020
Intravenous iron: a framework for changing the management of iron deficiencyMichael Auerbach, Anat Gafter-Gvili, Iain C Macdougall
The Lancet. Haematology|August 28, 2020
Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trialDonald M Arnold, Nancy M Heddle, Richard J Cook, et al.
The Lancet. Haematology|March 9, 2020
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trialEytan M Stein, Amir T Fathi, Courtney D DiNardo, et al.
The Lancet. Haematology|June 2, 2022
Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trialPablo L Ortiz-Romero, Lidia Maroñas Jiménez, Cristina Muniesa, et al.
The Lancet. Haematology|May 5, 2022
An integrated approach to cardioprotection in lymphomasMaja V Maraldo, Mario Levis, Alessandro Andreis, et al.
The Lancet. Haematology|October 10, 2021
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 studyChristiane Querfeld, John A Thompson, Matthew H Taylor, et al.
The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.
The Lancet. Haematology|May 2, 2022
The case for classical haematology: the impact of a name and the future of a fieldHanny Al-Samkari, Alison W Loren, Alfred I Lee
The Lancet. Haematology|July 5, 2016
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trialPatrick B Johnston, Betsy LaPlant, Ellen McPhail, et al.
Pageof 73